BRCAONE 150mg Tablet Global Supply Framework
🌍 Global Procurement Overview
Are you looking to streamline your international oncology supply line with a highly secure, regulatory-compliant partner for targeted cancer therapeutics?
Ernest Impex (the specialized global distribution division operating under the Group of Ernest Pharmaceutical Pvt. Ltd.) is a premier international exporter, bulk supplier, and licensed distributor of BRCAONE 150mg Tablets (Olaparib). Manufactured by Emcure Pharmaceuticals Ltd., BRCAONE represents a highly sought-after, cost-effective global alternative for targeted oncology protocols.
.
🔬 Technical Product Profile & Long Information: BRCAONE 150mg
BRCAONE 150mg contains Olaparib as its active pharmaceutical ingredient (API).
⚙️ Mechanism of Action (How it Operates)
BRCAONE 150mg functions through a highly sophisticated, cell-selective biological mechanism known as synthetic lethality:
Inhibition of PARP Single-Strand Repair: The active molecule, Olaparib, selectively binds to and inhibits the PARP enzymes responsible for repairing single-strand DNA breaks.
When PARP is blocked, these single-strand breaks remain unrepaired and convert into complex double-strand DNA breaks during cellular replication cycles. PARP Trapping: Beyond simple enzymatic inhibition, BRCAONE traps the PARP protein directly onto the damaged DNA site. This creates a physical cellular obstruction that stalls replication forks, inducing severe genomic instability within the replicating tumor cells.
Exploiting Synthetic Lethality: In normal cells, double-strand breaks are easily mended via the Homologous Recombination Repair (HRR) pathway (mediated by BRCA1 and BRCA2 genes). However, in cancer cells possessing mutant or deficient BRCA genes, this repair loop is broken.
Unable to repair the double-strand breaks induced by PARP trapping, the malignant cell line is forced directly into programmed cell death (apoptosis), selectively sparing healthy, repair-competent tissue.
📋 Therapeutic Indications
BRCAONE 150mg Tablets are globally sourced and utilized under specialist supervision for several critical maintenance and treatment lines:
Ovarian Cancer: Deployed as an advanced maintenance monotherapy for adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancers who are in complete or partial response to first-line or recurrent platinum-based chemotherapy lines.
Breast Cancer: Indicated for the treatment of adult patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
Prostate Cancer: Sourced for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) showing progression following prior anti-androgen therapy.
Pancreatic Cancer: Utilized for the first-line maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on a minimum of 16 weeks of a first-line platinum-based chemotherapy regimen.
⚠️ Side Effects & Safety Profile
Given its high structural potency and systemic action on cellular replication, therapy with BRCAONE 150mg must be strictly monitored by a clinical oncologist. Known clinical risks include:
Hematological Toxicity (Myelosuppression): Clinically significant drops in systemic blood cell counts, manifesting as Anemia (decreased red blood cells), Neutropenia (low white blood cells, elevating susceptibility to opportunistic infections), and Thrombocytopenia (low blood platelets, causing unusual bruising or bleeding patterns).
Gastrointestinal & Systemic Manifestations: Mild to moderate nausea, vomiting, profound fatigue, asthenia (weakness), diarrhea, loss of appetite (anorexia), dyspepsia, headache, and dysgeusia (taste distortion).
Serious Complications: Rare but critical risks include pneumonitis (interstitial lung disease presenting as sudden breathlessness or cough) and long-term hematological malignancies such as Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).
Teratogenicity Risk: Highly toxic to fetal development.
Female patients of reproductive potential must verify negative pregnancy status prior to treatment initiation and maintain highly effective double-barrier contraception protocols during treatment and for at least 6 months following the final dose. Male patients must refrain from sperm donation for at least 3 months post-therapy.
📦 Storage, Stability & Commercial Packaging
To ensure absolute chemical stability, purity, and shelf-life compliance across long-haul international shipping corridors:
Temperature Protocols: Store below 30°C (86°F) inside climate-controlled wholesale facilities.
Protect from freezing and extreme thermal fluctuations. Moisture Control: Maintain tablets inside their original, moisture-impermeable, factory-sealed bottle or blister presentation. Avoid exposure to high humidity spikes or direct UV radiation.
Commercial Presentation: Supplied under the Emcure Pharmaceuticals brand line, typically configured as 60 tablets per container bottle.
🚛 Bulk Logistics & Indian Export Excellence
Validated GMP Manufacturing: Every shipment of BRCAONE 150mg exported by Ernest Impex is directly sourced from state-of-the-art, regulatory-approved facilities working in absolute alignment with international Good Manufacturing Practices (GMP).
End-to-End Customs Management: Our experienced pharmaceutical logistics desk efficiently manages country-specific import documentation, drug classification frameworks, and customs clearance procedures for rapid entry into the US, UK, EU, ASEAN, and Caribbean zones.
Complete Compliance Dossier: High-volume institutional and commercial orders ship with comprehensive verification documents, including authentic Certificates of Analysis (COA), batch manufacture numbers, stamped commercial invoices, and origin certificates.
PRESCRIPTION MEDICINE : YES
Disclaimer: BRCAONE 150mg Tablet is a strictly regulated, high-potency prescription antineoplastic medication.
It must be administered exclusively under the direct prescription, intervention, and continuous laboratory monitoring of a certified oncologist or hematologist. The trade data published across this platform is intended solely for international B2B procurement research, global wholesale logistics formulation, and institutional sourcing awareness; it does not constitute or replace professional medical diagnosis, patient screening, or clinical advice from a certified healthcare practitioner.
📞 Contact Ernest Impex — Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
🌐 Websites:
📧 Email:
exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
📲 WhatsApp Link:
https://wa.me/919359902383
